Use of anti-r3hdm2 antibodies in the diagnosis or screening of seronegative rheumatoid arthritis

By using anti-R3HDM2 antibody and protein microarray technology, the diagnostic challenge of seronegative rheumatoid arthritis has been solved, the positive diagnostic rate has been improved and the risk of misdiagnosis has been reduced, and an early diagnostic tool has been provided.

CN122410044APending Publication Date: 2026-07-17PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-22
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Current technology is insufficient to effectively diagnose seronegative rheumatoid arthritis, causing some patients to miss the optimal treatment window and resulting in poor prognosis.

Method used

Using anti-R3HDM2 antibody as a biomarker, the anti-R3HDM2 antibody in the test samples was detected by methods such as protein/peptide chip detection and enzyme-linked immunosorbent assay, and then validated by protein microarray technology, to achieve the diagnosis or screening of serum-negative rheumatoid arthritis.

Benefits of technology

It improved the diagnostic positivity rate of seronegative rheumatoid arthritis from around 70% to over 77%, significantly reducing the risk of misdiagnosis and providing an early diagnostic tool.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

本发明属于生物检测领域，具体涉及抗R3HDM2抗体在诊断或筛查血清阴性类风湿关节炎中的应用。本发明首次公开了抗R3HDM2抗体作为血清阴性类风湿关节炎的诊断或筛查的标志物，通过检测上述标志物的含量可以实现对血清阴性类风湿关节炎的诊断或筛查。
Need to check novelty before this filing date? Find Prior Art